DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)

Fibrous Dysplasia Clinical Trial

— DeFiD  

Official title:

DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD): a Randomized Double-blind Placebo-controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05966064
• Other study ID #: 2022-501705-12-00
• Status: Recruiting
• Phase: Phase 4
• Start date: June 13, 2023
• Est. completion date: June 2025

Study information

• Verified date: July 2023
• Source: Leiden University Medical Center
• Contact: Natasha Appelman-Dijkstra, MD, PhD
• Phone: +31 625301410
• Email: n.m.appelman-dijkstra[@]lumc.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fibrous Dysplasia/McCune-Albright syndrome (FD/MAS) is a rare disease, consisting of the replacement of normal bone tissue with fibrous tissue. FD lesions may be isolated in one or more bones or may be associated with endocrinopathies in McCune-Albright syndrome. Bone lesions constitute of weak bone tissue, leading to higher risk of fractures, pain and decreased quality of life. There is no cure for FD lesions and current therapies failed to soothe patients' complaints or to display any effect on progression of the lesions on imaging. However, the RANKL-inhibitor Denosumab demonstrated encouraging results in mouse models and in off-label clinical use, leading to clinical, biochemical and radiographical improvements.

Study's aim is to investigate whether 3-monthly Denosumab will improve the clinical, radiological and biochemical manifestations of FD bone lesions.

Description:

Eligible patients will be randomized to treatment with either subcutaneous Dmab 120mg or placebo at baseline and 3 months in a blinded fashion. At 6 months, after 2 injections, patients with pain score <4 will exit the study to discontinue study medication and proceed in usual care, while patients with pain score ≥4 or lesional growth will be offered Dmab 120 mg at 6 and 9 months in an open-label design.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 82
• Est. completion date: June 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Symptomatic patients with established diagnosis of FD/MAS and closed growth plates(>18 years)

• Pain in the region of an FD localization, not responding to adequate pain treatment and without mechanical component e.g. impending fracture

• Pain score from FD lesion for maximum or average pain on VAS = 4

• Increased lesional activity defined as increased bone turnover markers (ALP, P1NP or CTX) or increased activity on Na[18F]-PET/CT or bone scintigraphy in at least one lesion

• Normal levels of calcium, parathyroid hormone and vitamin D (supplementation is allowed)

• Treated hypophosphatemia (defined as >0.7 at two separate measures)

• good dental health (last check within the last 12 months)

Exclusion Criteria:

• Active pregnancy wish, pregnancy or nursing

• Pain not related to FD

• Uncontrolled endocrine disease

• Untreated vitamin D deficiency, hypocalcemia or hypophosphatemia

• Previous use of bisphosphonates or Dmab < 6 months before inclusion ('6 months wash out')

• Previously reported severe side effects on Dmab

• Inability to fulfil study requirements

• Poor untreated dental health without intention to get treatment

• Treatment with other bone influencing drugs, such as high doses corticosteroids

Related Conditions & MeSH terms

• Fibrous Dysplasia
• Fibrous Dysplasia of Bone
• McCune Albright Syndrome
• Syndrome

Intervention

Drug:
• Denosumab 120 Mg/1.7 Ml Inj
Denosumab randomized at baseline and after 3 months at 6 and 9 months in case of open label
• Placebo
placebo randomized at baseline and after 3 months

Locations

Country	Name	City	State
Netherlands	Leiden University Medical Center	Leiden

Sponsors (1)

Lead Sponsor	Collaborator
Natasha Appelman-Dijkstra

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Denosumab effect on maximal pain score	Evaluation of maximal pain score changes after treatment, assessed by Brief Pain Inventory (scale 0 to 10; 0-no pain, 10 worst pain)	at baseline, 3 months and after 6 months and in case of open label treatment after 9 and 12 months
Secondary	Denosumab effect on average pain scores	Evaluation of average pain score changes after treatment, assessed by Brief Pain Inventory (scale 0 to 10; 0-no pain,10 worst pain)	at baseline, 3 months and after 6 months and in case of open label treatment after 9 and 12 months
Secondary	To evaluate the number of patients with 50% reduction of maximal pain (BPI)	Evaluation of the number of patients with 50% reduction of maximal pain score changes after treatment, asseses by Brief Pain Inventory (scale 0 to 10; 0-no pain, 10 worst pain)	at baseline, 3 months and after 6 months and in case of open label treatment after 9 and 12 months
Secondary	Denosumab effect on quality of life	Evaluation of Denosumab effect on quality of life, assessed with validated questionnaire SF-36 (scale 0-100, higher scores indicate better health status)	at baseline, 3 months and after 6 months and in case of open label treatment after 9 and 12 months
Secondary	Denosumab effect on average weekly pain score	Evaluation of Denosumab effect on average weekly pain score assessed through a pain diary with VAS score (scale 0 to 10)	every week from baseline, through study completion, an average of 1 year
Secondary	Denosumab effect on Physical activity assessment assessed through Health Assessment Questionnaire - Disability Index	Evaluation of Denosumab effect on on Physical activity assessment (Health Assessment Questionnaire - Disability Index: Health state index scores generally range from less than 0 (where 0 is a health state equivalent to death; negative values are valued as worse than death) to 1 (perfect health), with higher scores indicating higher health utility, though health state preferences can differ between countries.	baseline, 3 months and 6 months, and in case of open label treatment after 9 and 12 months
Secondary	Denosumab effect on Physical activity assessment assessed through screenshot of pedometer	Evaluation of Denosumab effect on on Physical activity assessment ( screenshot of pedometer of activity during the last week on smartphone, unit measure: number of steps during the last week)	baseline, 3 months and 6 months, and in case of open label treatment after 9 and 12 months
Secondary	Evaluation of prevalence of possible neuropathic component of the reported pain	to evaluate the prevalence of possible neuropathic component of the reported pain through Pain Detect questionnaire (It is scored from 0 to 38, with total scores of less than 12 considered to represent nociceptive pain, 13-18 possible NeP, and >19 representing >90% likelihood of Neuropathic pain)	baseline, 3 months and 6 months and in case of open label treatment after 9 and 12 months
Secondary	To investigate the number of analgesics used for pain	number of used analgesics for pain : unit of measure: number	baseline, 3 months and 6 months and in case of open label treatment after 9 and 12 months
Secondary	To investigate the frequency use of analgesics for pain	the frequency use of analgesics for pain (daily, multiple times per day, multiple times per week, monthly, when necessary)	baseline, 3 months and 6 months and in case of open label treatment after 9 and 12 months
Secondary	To investigate the dosage of analgesics used for pain	dosage of analgesics used for pain (unit of measure: mg)	baseline, 3 months and 6 months and in case of open label treatment after 9 and 12 months
Secondary	Denosumab effect on serum bone markers	effect of denosumab on bone serum markers (alkaline phosphatase (measure unit: U/L), P1NP -Procollagen-1-propeptide (measure unit: ng/ml), Beta-crosslaps (measure unit: ug/L)	baseline, 3 months and 6 months and in case of open label treatment after 9 and 12 months
Secondary	Denosumab effect on serum markers	effect of Denosumab on serum calcium(mmol/L), fosfate (mmol/L), PTH (pmol/L)	baseline, 3 months and 6 months and in case of open label treatment after 9 and 12 months
Secondary	Denosumab effect on lesion size	Na18F-PET/CT scan- measurement of lesion size	baseline and after 6 months, and in the case of open label treatment after 12 months
Secondary	Denosumab effect on lesion activity	Na18F-PET/CT scan- ,measurement of Na18F uptake	baseline and after 6 months, and in the case of open label treatment after 12 months
Secondary	disease quantification (Skeletal Burden Score (SBS)	nuclear imaging ((Skeletal Burden Score (SBS): scale 0 to 75, higher scores meaning increased disease activity	at baseline, 6 months and after 12 months
Secondary	Denosumab effect on bone density	Dual-energy X-ray absorptiometry (DXA) - bone density measurement ( T-score of -1.0 or above = normal bone density T-score between -1.0 and -2.5 = low bone density, or osteopenia; T-score of -2.5 or lower = osteoporosis)	baseline and after 12 months
Secondary	Denosumab effect on vertebral fractures	Dual-energy X-ray absorptiometry (DXA) - assement of presence of Vertebral Fractures through Vertebral Fractures Assessment (VFA) and changes from baseline until 12 months after	baseline and after 12 months
Secondary	To assess potential side effects in the form of Atypical femoral fractures	Dual-energy X-ray absorptiometry (DXA) femur extended	after 12 months